Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I1ME
|
||||
| Former ID |
DNC013131
|
||||
| Drug Name |
10R-hydroxylobel-7-ene
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528364] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H27NO
|
||||
| Canonical SMILES |
CN1C(CCCC1C=CC2=CC=CC=C2)CC(C3=CC=CC=C3)O
|
||||
| InChI |
1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22-/m1/s1
|
||||
| InChIKey |
IKYXUFYHDWVXST-LRGONLHBSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent dopamine transporter | Target Info | Inhibitor | [528364] | |
| Sodium-dependent serotonin transporter | Target Info | Inhibitor | [528364] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.